Romania

Back to map

Population: 21,400,000

Largest cities: Bucharest (capital), Iasi, Brasov, Cluj-Napoca, Timisoara, Constanta

Approval Process

Romania, although a new member of European Union, has many years of experience in conducting clinical trials. The legislation on clinical trials is harmonized with the EU and the EU Clinical Trials Directive was transposed into national legislation in 2004.

  • realistic start-up time: 5.5 months
Recruitment Potential

As the fourth most populated European country it offers a significant pool of motivated, compliant and mostly treatment-naïve subjects, especially in:

  • infectious diseases – prevalence of hepatitis B in Romania is one of the highest rates in Europe
  • cancers – the highest incidence of cervical cancer in Europe
  • cardiovascular and respiratory disorders
  • diabetes – there are 800,000 patients registered and at least 600,000 have diabetic neuropathy; less than 50% of patients are being treated

Estimated deaths per 100,000 population by cause (higher than world/European average):

Estimated deaths per 100,000 population by cause (higher than world/European average):

Diseases Romania World Average Europe Average
Cardiovascular diseases 753.7 240.9 465.2
Neoplasms 236.0 222.1 236.2
Digestive diseases 82.8 32.0 30.9
Genitourinary diseases 25.1 18.8 20.1
Mental and substance use disorders 6.4 4.3 11.1

Data from World Health Organization

Patients are motivated to participate in clinical trials because of the opportunity to access effective drug therapy, reduced treatment costs, closer medical follow up and significantly better overall medical care.

Investigators and Sites

There are approximately 460 sites in Romania, including over 50 private and public sites located in Bucharest. The Romanian investigators are appropriately qualified by education, training and experience. They are ICH GCP experienced, highly motivated and deliver very high quality data. Majority of the Romanian CRAs are physicians,  biologists or nurses, which leads to excellent relations with the investigators and excellent quality and understanding of the data.